Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study

European Journal of Pharmacology

Volumn 337, Issue 1, 1997, Pages 111-114

  Mukherjee, Jogeshwar ^a   Yang, Zhi Ying ^a  

^a Franklin McLean Memorial Research Institute   (United States)

Author keywords

Fluoxetine; Monoamine Oxidase B; N (6 18F fluorohexyl) N methylproparglyamine; Norfluoxetine

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CITALOPRAM; CLORGYLINE; FLUOXETINE; RADIOLIGAND; SELEGILINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; FLUOXETINE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030727323     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01233-8     Document Type: Article

References (16)

1. Caccia S., Cappi M., Fracasso C., Garattini S. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology. 100:1990;509-514.
2. Cooper, J.R., Bloom, F.E., Roth, R.H., 1996. The Biochemical Basis of Neuropharmacology, 7th ed. Oxford University Press, New York, NY, pp. 487-495.
3. 3H ]cyanoimipramine for quantitative measurement of serotonin transporter sites in human brain Neuropsychopharmacology. 14:1996;309-323.
4. Harvey, R.A., Champe, P.C., Mycek, M.J., Gertner, S.B., Perper, M.M., 1992. Pharmacology. J.B. Lippincott, New York, NY, pp. 119-126.
5. Kapur S., Mann J.J. Role of the dopaminergic system in depression. Biol. Psychiatry. 32:1992;1-17.
6. Karson C.N., Newton J.E.O., Livingston R., Jolly J.B., Cooper T.B., Sprigg J., Komoroski R.A. Human brain fluoxetine concentrations. J. Neuropsychiatry Clin. Neurosci. 5:1993;322-329.
7. Knoll J., Magyar K. Some puzzling pharmacological effects of monoamine oxidase inhibitors. Adv. Biochem. Psychopharmacol. 5:1972;393-408.
8. Konradi C., Svoma E., Jellinger K., Riederer P., Denney P., Thibault J. Topographic immunocytochemical mapping of monoamine oxidase A, monoamine oxidase B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience. 26:1988;791-802.
9. Leonardi E.T.K., Azmitia E.C. MDMA (Ecstasy) inhibition of MAO type A and type B: Comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology. 10:1994;231-238.
10. Munson P.J., Rodbard D. LIGAND: A versatile approach for the characterisation of ligand binding systems. Anal. Biochem. 107:1980;220-239.
11. 3H ]Ro 19-6327 in vitro: Localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain J. Neurosci. 12:1992;1977-1999.
12. 3H ]paroxetine J. Neurochem. 52:1989;1605-1612.
13. Wong D.T., Bymaster F.P., Reid L.R., Mayle D.A., Krushinski J.H., Robertson D.W. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain. Neuropsychopharmacolgy. 8:1993;337-344.
14. Wong D.T., Bymaster F.P., Engleman E.A. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug; Twenty years since its first publication. Life Sci. 57:1995;411-441.
15. Yu, P.H., 1986. Monoamine oxidase. In: Boulton, A.A., Baker, G.B., Yu, P.H. (Eds.), Neuromethods: Neurotransmitter Enzymes, vol. V. Humana Press, Clifton, NJ, pp. 235-272.
16. Yu P.H., Davies B.A., Boulton A.A. Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity. Biochem. Pharmacol. 46:1993;753-757.